A prespecified interim analysis from the phase 3 HARMONi-2 trial found ivonescimab outperformed pembrolizumab in PD-L1-positive advanced non-small cell lung cancer, delivering median overall survival of 30.8 months versus 22.6 months. The update places the bispecific approach in direct competition with PD-1 monotherapy in a biomarker-selected population and may influence first-line treatment strategies for tumors meeting PD-L1 thresholds. Analysts will likely focus on the full dataset as follow-up matures, including progression-free survival, response durability, and safety comparisons that could determine whether the OS separation holds in broader clinical and regulatory discussions.